Cart
sales@molnova.com
DL-Buthionine-(SR)-sulfoximine
CAS No. 5072-26-4
DL-Buthionine-(SR)-sulfoximine( Butionine sulfoximine | NSC 381100 )
Catalog No. M20963 CAS No. 5072-26-4
DL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 31 | In Stock |
|
| 50MG | 43 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDL-Buthionine-(SR)-sulfoximine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.
-
DescriptionDL-Buthionine-(SR)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase for the treatment of solid tumors.
-
In Vitro——
-
In Vivo——
-
SynonymsButionine sulfoximine | NSC 381100
-
PathwayOthers
-
TargetOther Targets
-
Recptorγ-glutamylcysteine synthetase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5072-26-4
-
Formula Weight222.31
-
Molecular FormulaC8H18N2O3S
-
Purity>98% (HPLC)
-
SolubilityH2O:41.67 mg/mL (187.44 mM; Need ultrasonic)
-
SMILESCCCCS(=N)(=O)CCC(N)C(=O)O
-
Chemical Name2-amino-4-(butylsulfonimidoyl)butanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Arrick B. A . Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis[J]. Journal of Experimental Medicine 1981 153(3):720-725.
molnova catalog
related products
-
4-IBP
4-IBP is a selective σ1 agonist with a high level of affinity for the σ1 receptor (Ki = 1.7 nM) and a moderate affinity for the σ2 receptor (Ki = 25.2 nM) .
-
C004019
C004019 is a small molecule PROTAC capable of targeting tau for selective protein degradation from the cell, while recruiting tau and E3 ligase (Vhl) for selective enhancement of tau ubiquitination and proteollyzation. C004019 is a candidate for AD and related tau protein diseases.
-
CFP10 (71-85)
CFP10 (71-85)
